Related Experiment Videos
Effects of alpha-interferon on serum beta-2-microglobulin
K Remes1, A Tienhaara, T T Pelliniemi
1Department of Medicine, Turku University of Central Hospital, Finland.
Leukemia & Lymphoma
|April 1, 1996
Summary
Serum beta-2-microglobulin (B2M) levels rise during interferon alpha treatment. This increase negates B2M's utility for monitoring disease activity in multiple myeloma and myeloproliferative diseases.
Area of Science:
- Immunology
- Oncology
- Biochemistry
Background:
- Beta-2-microglobulin (B2M) is a light chain of HLA class I antigens, shed into blood during HLA molecule turnover.
- Elevated serum B2M is observed in renal diseases, malignancies, and inflammatory/autoimmune disorders.
- Serum B2M holds prognostic significance in lymphatic malignancies.
Purpose of the Study:
- To investigate the effect of interferon alpha (IFN alpha) treatment on serum B2M levels.
- To evaluate the impact of IFN alpha on B2M's role as a disease activity biomarker.
Main Methods:
- Serum B2M levels were measured in patients undergoing IFN alpha therapy.
- Patients included those with multiple myeloma and chronic myeloproliferative diseases.
Main Results:
- IFN alpha treatment led to a significant increase in serum B2M concentrations.
- The rise in B2M levels was observed in both multiple myeloma and myeloproliferative disease cohorts.
Conclusions:
- Interferon alpha therapy diminishes the value of serum B2M as a reliable indicator of disease activity.
- Clinical interpretation of serum B2M levels requires consideration of concurrent IFN alpha treatment.